CompanyHealth
Pheast Therapeutics
Pheast Therapeutics is a clinical-stage biotech engineering the innate immune system to attack cancer. Its lead drug, PHST001, is an anti-CD24 macrophage checkpoint inhibitor designed to flip the 'don't eat me' signal that solid tumors use to hide from the body's first-line defenders.
2020Founded
Redwood CityHQ
$76,000,000Series A
biotechimmunotherapycancermacrophagecd24checkpoint-inhibitor